Article Text

Download PDFPDF

4CPS-168 Results of the use of galcanezumab in routine clinical practice
  1. P Tardáguila Molina,
  2. C Dean Barahona,
  3. M Blanco Crespo,
  4. E Martinez Ruiz,
  5. A Miranda Del Cerro,
  6. GI Casarrubios Lázaro,
  7. A Codonal Demetrio,
  8. FJ Pro Jimenez
  1. Guadalajara University Hospital, Pharmacy, Guadalajara, Spain


Background and Importance Migraine is a highly disabling neurovascular disorder characterised by a severe headache and trigeminovascular system activation, involving the release of calcitonin-gene related peptide (CGRP). Galcanezumab is a humanised monoclonal antibody blocking the CGRP.


  • The effectiveness of galcanezumab in the prophylaxis of chronic migraine

  • Response to other anti-CGRP monoclonal antibodies after galcanezumab failure

Material and Methods Observational-retrospective study from January 2020 to September 2022. Patients in whom at least one year had passed since the start of galcanezumab treatment were included.

Variables analysed: demographics, baseline migraine days/month (MDM), three months later, objective response rate (ORR) >50%, duration, reason for suspension, and action. The headache impact test (HIT-6) was performed at baseline vs after three months of treatment. This score presents a range between 36 and 78 (<49= little or no impact, 50-55= certain impact, 56-59= important impact, >60= very severe impact).

Quantitative variables were expressed as median (interquartile range).

Results 56 patients were included.

- 9%(5) of the patients continue with active treatment, 100% maintain effectiveness, median MDM: 3(2-6).

- 91% (51) discontinued treatment:

Conclusion and Relevance A high percentage of patients presented a good response to galcanezumab, with an improvement in the HIT-6 score.

A large number of patients who received temporary prophylaxis with galcanezumab did not require another visit to the neurologist. Most of the patients who required reintroduction of galcanezumab reached an ORR>50%.

Less than half of the patients who restarted therapy with a different anti-CGRP after galcanezumab failure, achieved an ORR>50%.

All patients who continued with galcanezumab from the start, maintained effectiveness of the treatment

Conflict of Interest No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.